HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harmony Biosciences Holdings Inc (HRMY) presents a solid long-term buying opportunity for a beginner investor with $50,000-$100,000 available for investment. Despite recent price weakness and litigation concerns, hedge fund buying momentum, positive analyst sentiment, and a bullish technical setup support the stock's potential for future growth. The lack of immediate AI or SwingMax trading signals does not diminish its long-term appeal.
The technical indicators suggest a mildly bullish trend. The MACD is positive and contracting, indicating potential upward momentum. The RSI is neutral at 45.419, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its support level of 32.437, with resistance at 35.455.
Hedge funds are aggressively buying, with a 18208.08% increase in buying activity over the last quarter.
Analysts have raised price targets significantly, with Oppenheimer setting a target of $72, citing strong IP defense and growth potential for Wakix.
Positive sentiment around IP litigation outcomes and the company's sales force expansion.
The stock has underperformed year-to-date, down 15%, compared to the XBI index up 12%.
No recent news or congress trading data to provide additional confidence.
No financial data available for analysis. However, analysts expect Wakix to achieve over $1B in FY26 revenue, supported by the company's strategic initiatives.
Analysts are generally positive on HRMY. Oppenheimer raised the price target to $72, citing strong IP defense. H.C. Wainwright reiterated a Buy rating with a $55 price target, viewing recent weakness as a buying opportunity. Truist raised the price target to $29 but maintains a Hold rating.
